Retatrutide + cagrilintide: what the stack rests on

Key takeaways

• No registered trial pairs these two drugs. As of July 16, 2026, ClinicalTrials.gov returns 33 studies listing retatrutide as an intervention and 42 listing cagrilintide, and zero listing both . Seventeen PubMed records name both, all of them class-wide reviews or meta-analyses .
• REDEFINE 1 (3,417 adults) measured what an amylin adds to an incretin, because it ran both drugs alone as separate randomized arms. Cagrilintide plus semaglutide reached -20.4 percent body weight at week 68 against -14.9 percent for semaglutide alone, an estimated difference of -5.5 percentage points (95% CI -6.7 to -4.3) .
• Gastrointestinal adverse events ran 79.6 percent on the combination, 73.8 percent on semaglutide alone, 54.0 percent on cagrilintide alone, and 39.9 percent on placebo .
• Retatrutide's obesity evidence is still phase 2, and thinner than the headline suggests: -24.2 percent at 48 weeks on 12 mg came from a 62-person arm of a 338-adult trial . Its one published phase 3 is a 40-week type 2 diabetes trial in 537 adults, where 12 mg produced -15.3 percent . Two obesity phase 3 trials have completed with no results posted , and the rest of the program is still running .
• Retatrutide's phase 2 randomized the starting dose as well as the target. Gut side effects were "partially mitigated with a lower starting dose (2 mg vs. 4 mg)", and at the same 8 mg target the slower start also landed lower at 48 weeks, -21.7 against -23.9 percent .

Skip to:

• Run them from two vials
• No registered trial pairs these two drugs
• REDEFINE 1 put a number on what an amylin adds
• One vial means one ratio you cannot adjust
• What each drug does on its own
• Bottom line

Run them from two vials

No registered trial pairs these two drugs

Searching ClinicalTrials.gov for studies that list retatrutide as an intervention returns 33 records. Cagrilintide returns 42. Cagrilintide together with semaglutide returns 33, which is the CagriSema program. Retatrutide together with cagrilintide returns zero .

Seventeen PubMed records name both drugs, and every one is a review, a meta-analysis, or a survey of obesity pharmacotherapy that discusses each drug separately . None of them reports the two being given together.

Amylin analogs are old ground. Pramlintide has carried an FDA-approved label since 2005 , and pairing an amylin analog with a glucose-lowering injectable is a well-worn idea. These two drugs, at these doses, premixed, have no evidence behind them.

REDEFINE 1 put a number on what an amylin adds

REDEFINE 1 comes closest to a controlled answer, because it ran the amylin, the incretin, and the combination as separate randomized arms and measured the differences. 3,417 adults were randomized 21:3:3:7 to cagrilintide plus semaglutide (2.4 mg of each), semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, for 68 weeks .

Adding cagrilintide to semaglutide moved the number from -14.9 to -20.4 percent, an estimated difference of -5.5 percentage points (95% CI -6.7 to -4.3, P<0.001). Adding semaglutide to cagrilintide moved it from -11.5 to -20.4, a difference of -8.9 points (95% CI -10.1 to -7.7) . The incretin side of the combination carries most of the result.

Applying that 5.5 to retatrutide assumes an amylin behaves the same bolted to a triple agonist as it does bolted to a single-receptor one. Semaglutide acts at the GLP-1 receptor. Retatrutide acts at three. REDEFINE 1's authors posit that their combination's effect comes from the complementary action of the two molecules on appetite regulation , which is a claim about semaglutide and cagrilintide, not about a triple agonist. Nobody has run the equivalent test with retatrutide, and a vendor's blend ratio is not evidence either way.

One vial means one ratio you cannot adjust

Retatrutide's phase 2 randomized participants to a target dose and to the route there: 4 mg starting from 2 mg against 4 mg starting from 4 mg, and 8 mg starting from 2 mg against 8 mg starting from 4 mg . Its conclusion on side effects was that gastrointestinal events were dose-related, mostly mild to moderate, and "partially mitigated with a lower starting dose (2 mg vs. 4 mg)".

One vial holds both drugs at one ratio, so every adjustment is a joint adjustment. If the amylin is what is making you sick at week six, cutting it means cutting the retatrutide with it, and in the closest analogue anyone has measured, cutting the amylin cost less than cutting the incretin . Two vials cost you a second injection and let you hold one drug steady while you move the other.

The pharmaceutical version of this pairing fixes the ratio too. CagriSema is a fixed-dose combination, delivered as the trial describes it, through "a dual-chamber, single-dose, single-use pen device". It started at 0.25 mg of each drug and co-escalated every 4 weeks to 2.4 mg of each by week 16, and investigators were permitted to delay escalation or reduce the dose when a participant reacted badly, with people allowed to continue at a submaximum dose . Novo built in 16 weeks of ramp and a documented way to back off, for a ratio they chose and gave to 2,108 people.

SYMLIN's label is explicit about mixing: pramlintide must not be mixed with insulin in the same syringe, because mixing can alter the pharmacokinetics of both products, and the label directs that they be given as separate injections . That instruction covers pramlintide and insulin, not cagrilintide and retatrutide, so it is a reason for caution rather than a finding about this blend.

Whether two peptides in one solution stay stable and absorb the way they do apart is a compatibility question with standard assays behind it. Nobody has published those results for cagrilintide and retatrutide .

What each drug does on its own

Retatrutide is a triple agonist at the GIP, GLP-1, and glucagon receptors. In its phase 2 in obesity (338 adults, 48 weeks, NCT04881760), 12 mg weekly produced a least-squares mean weight change of -24.2 percent at 48 weeks against -2.1 percent for placebo, with -17.5 percent reached by 24 weeks .

The 12 mg figure carries a caveat the headline hides: that arm held 62 people, out of 338 across the whole trial .

Its only published phase 3 is TRANSCEND-T2D-1 (Lancet, June 2026), a 40-week trial in 537 adults with type 2 diabetes, where 12 mg produced -15.3 percent body weight against -2.6 percent for placebo, and 2 to 5 percent discontinued for adverse events against 0 percent on placebo . It is the only retatrutide record PubMed indexes as a phase 3 trial . That trial ran in type 2 diabetes over 40 weeks against the phase 2's obesity population over 48, so -15.3 and -24.2 are not the same measurement.

Two obesity registrational trials have completed with no results posted to the registry: one in 2,335 adults and one in 445 adults with knee osteoarthritis . The rest of the obesity program is still running, including a 10,000-adult cardiovascular and kidney outcomes trial . The longest obesity result anyone has published remains that 48-week phase 2 . Both drugs are still in trials, and neither is FDA-approved .

• Cutaneous hyperesthesia and skin sensitivity adverse events were reported in 7 percent of retatrutide participants against 1 percent on placebo, and none were severe or serious .
• Heart rate increases were dose-dependent, peaked at 24 weeks, and declined after .
• Gut effects were dose-related and mostly mild to moderate, and the starting dose changed them at a fixed target .

Cagrilintide is a long-acting amylin analog. Its phase 2 randomized 706 participants across cagrilintide 0.3 to 4.5 mg (100 to 102 per dose group), liraglutide 3.0 mg (99), and placebo (101) over a 26-week treatment period. The top 4.5 mg dose produced -10.8 percent (11.5 kg) against -3.0 percent for placebo and -9.0 percent for liraglutide 3.0 mg .

Cagrilintide brings its own gastrointestinal profile. In that trial, gastrointestinal adverse events ran 41 to 63 percent across the cagrilintide dose groups against 32 percent on placebo, and nausea ran 20 to 47 percent against 18 percent . Adding it to a drug whose most common adverse events are already gastrointestinal puts two such profiles on top of each other.

Bottom line

Retatrutide has strong phase 2 obesity data, one published phase 3 in type 2 diabetes, and an obesity phase 3 program that has published nothing. Cagrilintide has decent phase 2 data and a phase 3 program built around a different partner drug. The pairing has neither. The best available estimate of what an amylin adds to an incretin is 5.5 percentage points for roughly 6 points more gastrointestinal trouble, measured with semaglutide , and whether that repeats on top of a triple agonist is unmeasured .

If you run it anyway, two vials is the whole recommendation. Separate vials keep the ratio adjustable. Start one drug at a time so a side effect has one obvious owner, and climb slowly: retatrutide's own trial found the lower start partially mitigated the gut effects, and the arm that produced its best 48-week number climbed from 2 mg . For the draw math, the peptide reconstitution calculator handles per-vial concentration, and GLP-1 reconstitution and titration risk covers where the unit conversions go wrong.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

See our Editorial process and contributor disclosure and our Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 12 entries, all primary canon, last reviewed 2026-07-16.

Related tools

• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Protocol builder overview - Public overview of the Pro protocol builder.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.